ArticleFrontiers in digital health2025
Interpretable AI-driven multi-objective risk prediction in heart failure patients with thyroid dysfunction.
Article in Frontiers in digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effect of exosome-related therapy in cardiac revascularization procedures: a systematic review.BMC cardiovascular disorders · 2025Pooled it
- Loss function influence on hyperparameter optimization for observational healthcare prediction models.Journal of the American Medical Informatics Association : JAMIA · 2026Article
- Mapping the research landscape of artificial intelligence in heart failure: a bibliometric analysis.Annals of medicine and surgery (2012) · 2026Article
- Explainable and Trustworthy Artificial Intelligence in Cardiology: A Narrative Review of Clinical Applications, Operational Integration, and Future Directions.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Heart Failure (HF) complicated by thyroid dysfunction presents a complex clinical challenge, demanding more advanced risk stratification tools. In this study, we propose an AI-driven machine learning (ML) approach to predict mortality and hospitalization risk in HF patients with coexisting thyroid disorders. Methods: Using a retrospective cohort of 762 HF patients (including euthyroid, hypothyroid, hyperthyroid, and low T3 syndrome cases), we developed and optimized several ML models-including Random Forest, Gradient Boosting, Support Vector Machines, and others-to identify high-risk individuals. Results: The best-performing model, a Random Forest classifier, achieved robust predictive accuracy for both 1-year mortality and HF-related hospitalization (area under the ROC curve ∼0.80 for each). We further employed model interpretability techniques (Local Interpretable Model-agnostic Explanations, LIME) to elucidate key predictors of risk at the individual level. This interpretability revealed that factors such as atrial fibrillation, absence of cardiac resynchronization therapy, amiodarone use, and abnormal thyroid-stimulating hormone (TSH) levels strongly influenced model predictions, providing clinicians with transparent insights into each prediction. Additionally, a multi-objective risk stratification analysis across thyroid status subgroups highlighted that patients with hypothyroidism and low T3 syndrome are particularly vulnerable under high-risk conditions, indicating a need for closer monitoring and tailored interventions in these groups. Discussion: In summary, our study demonstrates an innovative AI methodology for medical risk prediction: interpretable ML models can accurately stratify mortality and hospitalization risk in HF patients with thyroid dysfunction, offering a novel tool for personalized medicine. These findings suggest that integrating explainable AI into clinical workflows can improve prognostic precision and inform targeted management, though prospective validation is warranted to confirm realworld applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.